Canopy Growth Q1 Revenue Climbs 13%, Loss Shrinks 68% — Adjusted EBITDA Loss Cut to C$3.2M
CGC is trading near its 52-week low of $0.844 (15% above the low) on light trading volume (0.3× avg).
Summary
Canopy Growth reported Q1 FY2027 revenue of C$81.2 million, up 13% year-over-year, with net loss narrowing to C$14.6 million. Adjusted EBITDA loss improved 59% to C$3.2 million, and adjusted gross margin rose to 31%.
Key Events · Earnings and Guidance · CGC
-
Revenue Up 13% Across All Segments
Consolidated net revenue reached C$81.2M, driven by 22% growth in Canada medical cannabis, 10% in adult-use, 10% in international markets, and 6% at Storz & Bickel.
-
Net Loss Narrows 68% to C$14.6M
Net loss improved from C$44.9M to C$14.6M, with adjusted EBITDA loss shrinking 59% to C$3.2M — approaching breakeven.
-
Adjusted Gross Margin Jumps to 31%
Adjusted gross margin rose from 25% to 31%, reflecting higher sales, cost rationalization, and MTL Cannabis synergies, despite VAC reimbursement headwinds.
-
Free Cash Outflow Widens on Working Capital
Free cash outflow increased to C$25.7M from C$11.6M, primarily due to timing of working capital changes, not operational deterioration.
Analysis · CGC · Life Sciences
A solid quarter for Canopy Growth, with revenue up 13% across all segments and the net loss shrinking by 68%. Adjusted EBITDA loss narrowed to just C$3.2 million, putting breakeven within reach. The improved gross margin and cost discipline show the MTL Cannabis integration is paying off, though free cash outflow widened on working capital timing. Against a backdrop of recent accounting restatements, a material weakness, and a pending reverse split vote to maintain Nasdaq listing, these results demonstrate operational momentum that strengthens the turnaround narrative.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CGC was trading at $0.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $415.3M. The 52-week trading range was $0.84 to $2.38. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.